Using over the counter medications for minor issues is common. Most consumers in Tennessee and elsewhere trust that the medications they take will reduce the effects of their ailment and cause minimal side effects, especially since the U.S. Food and Drug Administration approves these products. Unfortunately, this trust can be misplaced in some cases as OTC medications could have serious effects, including causing cancer.
Earlier this year, it was discovered the Zantac, a popular heartburn medication, and its generic versions contain a significant level of n-nitrosodimethylamine. NDMA is considered a probable carcinogen, which means that it could cause cancer in humans who consume it. In April, the FDA announced that Zantac and its generic versions should be taken off the market due to the significant levels of NDMA.
Now, Sanofi and GlaxoSmithKline, the makers of Zantac and its generic versions, are under investigation by the U.S. Department of Justice to determine whether the companies violated the False Claims Act by not disclosing the possible carcinogen in the product. Notice of the investigation was sent to the companies in June as well as requests for information. Neither company involved in the investigation provided a comment for the report.
Suffering serious side effects due to taking medications that were once perceived as safe can be a major setback for consumers. Developing cancer is likely something that most people did not anticipate from using a heartburn medication, but if this outcome has affected Tennessee residents, it may be warranted to take legal action against the liable parties. Due to the widespread use of Zantac and its generic versions, a class action lawsuit could suit this situation.